Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221345
Title: Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study
Author: Paja, Miguel
Soto, Alfonso
Hanzu, Felicia A.
Guerrero Pérez, Fernando
Cámara, Rosa
Moure, María Dolores
Gálvez, Ángeles
Simó Servat, Andreu
Villar Taibo, Rocío
Calatayud, María
Vicente, Almudena
Recio Córdova, Jose M.
Serra, Guillermo
Martín Rojas Marcos, Patricia
Parra Ramírez, Paola
Araujo Castro, Marta
Librizzi, Soledad
Irigaray, Ana
Ollero, María Dolores
Aznar, Silvia
Muñoz, Fernando
Aulinas, Anna
González Fernández, Laura
García Centeno, Rogelio
Egaña, Nerea
González Vidal, Tomás
Menéndez, Edelmiro
Delgado, Ana M.
Abarca, Javier
Sottile, Johana
Picó, Antonio
Novo, Cristina
Ortiz, Isabel
Tenorio, Carmen
León, Ricardo de
Pablos Velasco, Pedro de
Crespo, Cristina
Peñalver, David
Díaz Soto, Gonzalo
Puig-Domingo, Manel
Biagetti, Betina
Keywords: Malalties de la hipòfisi
Tumors
Pituitary gland diseases
Tumors
Issue Date: 21-Feb-2025
Publisher: Frontiers Media SA
Abstract: Background The outcomes of transsphenoidal surgery (TSS) for pituitary adenoma (PA) depend on many factors, including the availability of an expert team and the volume of surgeries performed. Data on the outcomes of TSS for PA are scarce in our country. TESSPAIN evaluates TSS outcomes in Spanish centers to assess the influence of surgical volume and specialized neurosurgical teams on success and complication rates. Methods A retrospective, nationwide, study of Spanish centers performing TSS between January 2018 and December 2022. Centers were classified as high volume (HV) [n=11, defined as centers with recognized expertise in Spain or those performing more than 25 TSS/year] or non-HV. Data collection included surgical success rates, complications, and pituitary adenoma resectability (R-PA). Additional analyses evaluated the impact of dedicated neurosurgical teams (DNT) within HV centers. Results A total of 2815 TSS from 29 Spanish centers were included (1421 NSPA, 436 GH-secreting, 323 Cushing's disease, 127 PRL-secreting and 25 TSH-secreting PA). The overall success rate was 50.5%, 76.8% for R-PA. HV centers had a higher overall success rate (53.1 vs. 47.7%; p=0.03). Better TSS outcomes for NSPA accounted for this difference. The overall TSS complication rate was 22.1%, which was higher for NSPA than for SPA (25.0 vs. 17.7%). The overall complication rate of TSS for PA was significantly higher in non-HV centers than in HV centers (24 vs 20.4.0; p <0.01). Centers with a DNT showed a trend to higher success rate in R-PA, while having a lower overall incidence of complications in TSS for PA than HV centers without a DNT (18.5 vs. 23.0; p=0.058), mainly reducing the rate of permanent ADH deficiency in all TSS for PA (2.7 vs. 8.4%; p<0.001). Conclusion Higher surgical volume and DNT are associated with improved TSS outcomes for PA in Spain. Our results support the recommendation of concentration of pituitary surgery in a reduced number of centers of expertise in our country in order to improve the success rate and reduce complications, mainly postoperative ADH deficiency.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fendo.2025.1529418
It is part of: Frontiers in Endocrinology, 2025, vol. 16
URI: https://hdl.handle.net/2445/221345
Related resource: https://doi.org/10.3389/fendo.2025.1529418
ISSN: 1664-2392
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
fendo-2-1529418.pdf1.34 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons